Stock listing

NASDAQ:RCKT Rocket Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Rocket Pharmaceuticals, Inc.

Follow Rocket Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:RCKT

$2.24 USD +0.06 (+2.8%)

Close on Oct 19, 2026

Since Jul 6, 2026 -43.9% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$2.17 – $2.29 USDOct 19, 2026
Volume
1.85M sharesOct 19, 2026
Market value
$245.9M USDAt the close on Oct 19, 2026 · price × 109.8M shares outstanding
Rocket Pharmaceuticals, Inc. logo
Ticker
NASDAQ:RCKT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Rocket Pharmaceuticals (NASDAQ:RCKT) Q2 2021 Earnings Call

    Mon, Aug 09, 2021 · 4:30 PM ET

    Watch Transcript

Latest news

Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference

Oct 15, 2026

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Oct 7, 2026

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

Oct 6, 2026

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

Sep 15, 2026

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

Aug 10, 2026

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

Aug 3, 2026

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Jun 12, 2026

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

May 7, 2026

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Apr 28, 2026

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I

Mar 30, 2026

All Rocket Pharmaceuticals, Inc. news

Financings

  • Term loan credit facility with warrants

    Oct 6, 2026

    Tranche closed: US$35M raised · warrants to purchase shares of Rocket's common stock · LifeSci Capital +1

    Dealers: LifeSci Capital, PJT

    Buyers: Hercules Capital, Inc. (credit facility for up to $150 million; $35 million funded at closing)

    Use of proceeds: Support the pivotal Phase 2 study of RP-A501 for Danon disease and advance the broader cardiovascular pipeline

    Tranche closed Oct 6, 2026

Read by 6ix AI from the company's releases

Decks

Rocket Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 182 in all · newest Oct 15, 2026 · oldest 2019
Calls
1 call with a replay · 1 with a transcript · latest Aug 9, 2021
Decks
39 decks · latest Oct 6, 2026

Where Rocket Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RCKT · Home listing · This pageNASDAQUnited StatesUSD
LS Exchange:A2JA9QLS ExchangeGermanyEUR
gettex:9IP1gettexGermanyEUR
Lang & Schwarz:A2JA9QLang & SchwarzGermanyEUR
BOATS:RCKTBOATSUnited StatesUSD
Tradegate:9IP1TradegateGermanyEUR
Dusseldorf:9IP1DusseldorfGermanyEUR
Frankfurt:9IP1FrankfurtGermanyEUR
Hamburg:9IP1HamburgGermanyEUR
Munich:9IP1MunichGermanyEUR
Stuttgart:9IP1StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Rocket Pharmaceuticals, Inc.